Rating Change
HC Wainwright & Co. reiterated its Buy rating on Intensity Therapeutics, Inc. (NASDAQ:INTS) on August 18, 2026.
reiterateNASDAQ:INTS
HC Wainwright & Co. Reiterates Buy Rating on Intensity Therapeutics, Inc. (INTS)
HC Wainwright & Co. reiterated its Buy rating on Intensity Therapeutics, Inc.
At publication ·
What changed
Intensity Therapeutics, Inc. (NASDAQ:INTS) · reiterate
- Firm
- HC Wainwright & Co.
- Rating
- Buy to Buy
- Price at event
- $4.27
- Market capitalization
- $28.3M
At a glance
Key takeaways
- HC Wainwright & Co. reiterated a Buy rating on Intensity Therapeutics (INTS) on August 18, 2026, with the stock trading at $4.26 and a market capitalization of $28.3 million.
Market Context
Intensity Therapeutics, Inc. operates in the Healthcare sector. The stock currently trades at $4.26 with a market capitalization of $28.3M.
Analyst coverage from HC Wainwright & Co. provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Intensity Therapeutics, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Intensity Therapeutics, Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 18, 2026 | HC Wainwright & Co. | Buy | N/A |
| Aug 20, 2025 | Benchmark | Speculative Buy | N/A |
| Aug 12, 2025 | Brookline Capital | Buy | N/A |
| Jan 13, 2025 | Alliance Global Partners | Buy | N/A |
| Nov 21, 2024 | HC Wainwright & Co. | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View INTS Stock Page
Frequently Asked Questions
What does the Buy rating mean for INTS?
A rating of Buy from HC Wainwright & Co. reflects the analyst's outlook on Intensity Therapeutics, Inc. (NASDAQ:INTS). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the INTS forecast page.